1. Home
  2. ABUS vs RYI Comparison

ABUS vs RYI Comparison

Compare ABUS & RYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ABUS
  • RYI
  • Stock Information
  • Founded
  • ABUS 2005
  • RYI 1842
  • Country
  • ABUS United States
  • RYI United States
  • Employees
  • ABUS N/A
  • RYI N/A
  • Industry
  • ABUS Biotechnology: Pharmaceutical Preparations
  • RYI Metal Fabrications
  • Sector
  • ABUS Health Care
  • RYI Industrials
  • Exchange
  • ABUS Nasdaq
  • RYI Nasdaq
  • Market Cap
  • ABUS 611.0M
  • RYI 699.3M
  • IPO Year
  • ABUS N/A
  • RYI N/A
  • Fundamental
  • Price
  • ABUS $3.37
  • RYI $21.79
  • Analyst Decision
  • ABUS Strong Buy
  • RYI Hold
  • Analyst Count
  • ABUS 3
  • RYI 1
  • Target Price
  • ABUS $5.67
  • RYI $25.00
  • AVG Volume (30 Days)
  • ABUS 636.5K
  • RYI 259.1K
  • Earning Date
  • ABUS 08-06-2025
  • RYI 07-29-2025
  • Dividend Yield
  • ABUS N/A
  • RYI 3.42%
  • EPS Growth
  • ABUS N/A
  • RYI N/A
  • EPS
  • ABUS N/A
  • RYI N/A
  • Revenue
  • ABUS $15,416,000.00
  • RYI $4,439,000,000.00
  • Revenue This Year
  • ABUS $3.35
  • RYI $0.68
  • Revenue Next Year
  • ABUS N/A
  • RYI $3.13
  • P/E Ratio
  • ABUS N/A
  • RYI N/A
  • Revenue Growth
  • ABUS 53.23
  • RYI N/A
  • 52 Week Low
  • ABUS $2.71
  • RYI $17.18
  • 52 Week High
  • ABUS $4.73
  • RYI $27.41
  • Technical
  • Relative Strength Index (RSI)
  • ABUS 54.05
  • RYI 49.55
  • Support Level
  • ABUS $3.33
  • RYI $20.60
  • Resistance Level
  • ABUS $3.45
  • RYI $23.01
  • Average True Range (ATR)
  • ABUS 0.12
  • RYI 0.87
  • MACD
  • ABUS 0.01
  • RYI 0.08
  • Stochastic Oscillator
  • ABUS 36.21
  • RYI 61.33

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

About RYI Ryerson Holding Corporation

Ryerson Holding Corp provides a metals service center, and value-added processor and is a distributor of industrial metals with operations in the United States, Canada, and Mexico. In addition to its North American operations, it conducts processing and distribution operations in China. Its customers range from local, independently owned fabricators and machine shops to large, international original equipment manufacturers. It carries a full line of products in stainless steel, aluminum, carbon steel, and alloy steels and a limited line of nickel and red metals in various shapes and forms. The company generates substantially all of its revenue from sales of metal products. Geographically, the majority revenue is generated from the United States.

Share on Social Networks: